Disease or Syndrome
Wave Life Sciences Reports Positive Interim Data for Duchenne Muscular Dystrophy Treatment
Wave Life Sciences, Duchenne Muscular Dystrophy, DMD, Exon 53 Skipping, WVE-N531, FORWARD-53 Clinical Trial, Interim Data, Muscle Health, Dystrophin Expression
Aptadir Therapeutics Unveils Novel RNA Inhibitors to Combat Cancer and Genetic Disorders
Aptadir Therapeutics, RNA inhibitors, DNMT1 interacting RNAs (DiRs), Cancer treatment, Genetic diseases, Epigenetic targeting, RNA therapeutics
Metsera’s Long-Acting GLP-1 Drug Shows Promising 7.5% Weight Loss in 36 Days, Paving Way for Monthly Dosing
Metsera, GLP-1, obesity treatment, long-acting drug, weight loss, monthly dosing, MET-097, clinical trial results.
Biohaven Achieves Breakthrough in Spinocerebellar Ataxia Treatment with Positive Pivotal Study Results for Troriluzole
Biohaven, Troriluzole, Spinocerebellar Ataxia (SCA), Pivotal Study Results, Neurodegenerative Disease, FDA Submission, New Drug Application (NDA)
AI Guidance for Investors: Navigating the Future with Strategic Approaches and Regulatory Insights
AI Guidance for Investors, Strategic AI Adoption, Regulatory Impact on AI, Cybersecurity Risks in AI, AI Mapping Strategies, Data Governance in AI, Future of AI in Healthcare
Telix Acquires RLS to Bolster Radiopharmaceutical Manufacturing and Distribution in North America
Telix Pharmaceuticals, RLS (USA) Inc., radiopharmaceutical manufacturing, distribution, acquisition, North America, radiometal production network
Biohaven Revives Troriluzole Hopes with Positive Update for Spinocerebellar Ataxia
Troriluzole, Spinocerebellar Ataxia (SCA), Biohaven Pharmaceuticals, Neurodegenerative Disorders, FDA New Drug Application (NDA), Clinical Trials, Rare Diseases
FDA Approves Bimzelx for Expanded Indications: Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Bimzelx, FDA approval, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A and IL-17F inhibitor
Athira Pharma Shifts Focus to ALS After Alzheimer’s Setback, Cuts 70% of Workforce
Athira Pharma, Alzheimer’s disease, ALS, layoffs, biotech, neurodegenerative diseases, small molecule therapy
BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis
KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.